The authors performed a one-sequence cross-over study to assess the absolute bioavailability and pharmacokinetics or oral docetaxel and encequidar, compared to IV docetaxel. This study enrolled patients with metastatic prostate cancer who were receiving IV docetaxel into three different cohorts with Oradoxel dose-escalation: 75 mg/m2 in Cohort 1, 150 mg/m2 in Cohort 2, and 300mg/m2 in Cohort 3. Oradoxel was given 3 weeks before or after IV docetaxel treatment. Intensive pharmacokinetic samples were taken on days 1-5 for Oradoxel and days 1-4 for IV docetaxel. Dose-limiting toxicity (DLT) or serious adverse events (SAE) were assessed per CTCAE v4.03.
While 11 men were initially included, each cohort included three evaluable patients (n=9). Pharmacokinetic parameters of Oradoxel vs IV docetaxel are summarized in the table below.
The mean absolute bioavailability of Oradoxel was 15.9% (range 8-25%) while pharmacokinetics became nonlinear at 300mg/m2. The authors identified no DLT, MTD, or drug-related SAE.
The authors conclude that Oradoxel was well tolerated. Further, oral dosing may be able to achieve equivalent exposure to intravenous administration of docetaxel. These data form the basis of further evaluation in phase 2 studies.
Presented by: Christopher G. Jackson, FRACP, University of Otago, Dunedin, New Zealand
Written by: Christopher J.D. Wallis, MD, Ph.D., Urologic Oncology Fellow, Vanderbilt University Medical Center, Twitter: @WallisCJD at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting #ASCO21, June, 4-8, 2021